Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | VHL | P40337 | 1/20 | 0.35 |
| ▸ | ELOC | Q15369 | 1/20 | 0.35 |
| ▸ | ELOB | Q15370 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350958 | 0.86 | ELANE (0.49) | ELANE | |
| SCHEMBL17578582 | 0.86 | ELANE (0.49) | ELANE | |
| SCHEMBL8348956 | 0.86 | ELANE (0.47) | ELANEGABRB1GABRB2 | |
| SCHEMBL17578454 | 0.86 | ELANE (0.47) | ELANEGABRB1GABRB2 | |
| SCHEMBL12055242 | 0.75 | CYP3A4 (0.55) | — | |
| SCHEMBL17578617 | 0.75 | CYP3A4 (0.55) | — | |
| SCHEMBL12055118 | 0.73 | ELANE (0.43) | ELANE | |
| SCHEMBL1536467 | 0.71 | ELANE (0.45) | ELANECTSSCTSKVHLELOC | |
| SCHEMBL8349766 | 0.71 | ELANE (0.47) | ELANE | |
| SCHEMBL12054740 | 0.71 | ELANE (0.45) | ELANECTSSCTSKVHLELOC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299094-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-7449479-B2 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311482-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | ELANE 2012/4885CTSB 124/4885CTSS 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.